Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure

Journal of the American Society of Nephrology

Volumn 13, Issue 2, 2002, Pages 461-469

  Kronenberg, Florian ^a   Kuen, Erich ^a   Ritz, Eberhard ^a   König, Paul ^a   Kraatz, Günter ^a   Lhotta, Karl ^a   Mann, Johannes F E ^a   Müller, Gerhard A ^a   Neyer, Ulrich ^a   Riegel, Werner ^a   Riegler, Peter ^a   Schwenger, Vedat ^a   Von Eckardstein, Arnold ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A4; CREATININE; IOHEXOL; UREA;

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; UREA BLOOD LEVEL;

EID: 0036154170     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Apolipoprotein A-IV. A protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification
2. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma
3. Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid
4. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma
5. Apolipoprotein A-IV synthesis in rat intestine: Regulation by dietary triglyceride
6. Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation
7. Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior
8. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice
9. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from another analog of phosphatidylcholine
10. Apolipoprotein A-IV: A determinant for binding and uptake of high density lipoproteins by rat hepatocytes
11. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells
12. Activation of lecithin: Cholesterol acyltransferase by human apolipoprotein A-IV
13. Activation of lecithin: Cholesterol acyltransferase by apolipoproteins E-2, E-3 and A-IV isolated from human plasma
14. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV
15. Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity
16. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV
17. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV
18. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease
19. Increased lipoprotein-remnant formation in chronic renal failure
20. An increased apo A-IV serum concentration of patients with chronic renal failure on hemodialysis
21. Plasma apolipoprotein A-IV metabolism in patients with chronic renal disease
22. Plasma cholesterol metabolism in end-stage renal disease: Difference between treatment by hemodialysis or peritoneal dialysis
23. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis
24. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure
25. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men
26. Effect of sample storage on the measurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides
27. Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease
28. Prediction of creatinine clearance from serum creatinine
29. Human apolipoprotein A-IV quantitation by sandwich enzyme linked immunosorbent assay
30. Tissue sites of degradation of high density lipoprotein apolipoprotein A-IV in rats
31. Effects of age, gender, and lifestyle factors on plasma apolipoprotein A-IV concentrations
32. Apolipoprotein A-IV levels and phenotype distribution in NIDDM
33. Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM
34. Apolipoprotein AIV: A potent endogenous inhibitor of lipid oxidation
35. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice
36. Atherosclerosis and arteriosclerosis in chronic renal failure
37. Hyperhomocysteinemia in endstage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
38. Homocysteine, lipoprotein(a) and fibrinogen: Metabolic risk factors for cardiovascular complications of chronic renal disease
39. Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: Critical impact of true glomerular filtration rate
40. Chronic renal transplantation: A model for the hyperhomocysteinemia of renal insufficiency
41. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study
42. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients
43. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
44. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
45. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
46. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients
47. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease
48. Apolipoprotein B, fibrinogen, HDL cholesterol and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients
49. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up
50. Is renal insufficiency an atherogenic state? Reflections on prevalence, incidence, and risk
51. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency
52. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis
53. Serum apolipoprotein profile of patients with chronic renal failure
54. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure